Izumi Biosciences LLC

Founded 2011

Employees 2

Follow

Overview

Izumi’s IND-stage product, with patent protection until 2033, combines: 1. reformulated elacridar, a clinical stage penetration enhancer, and 2. imatinib, an FDA approved molecularly targeted therapeutic. The product crosses the blood-organ barrier to treat patients with neurofibromatosis type-1 (NF1). An FDA approved product will offset high direct costs, be prescribed by specialists, and reimbursed by insurers.

Management Team

President & CEO

Ton (Antonius) Bunt

Ton is an MD PhD, who led a biotech turnaround, with a new strategic plan, and financing. He completed six licensing and M&A transactions with over $1B in cumulative value. As head of R&D at specialty pharma companies, he achieved clinical and regulatory milestones, incl. a Special Protocol Assessment with FDA, pivotal studies, and sNDA approvals. Product development, marketing, and leadership experience at Novartis in Europe and Merck in the US.

General counsel & CBO

Robert Anderson

Bob is both a CPA and corporate lawyer with extensive international experience in technology transfer, licensing, collaborative research and clinical trial agreements and mergers and acquisitions, most recently at Abbott Laboratories. As General Counsel for BASF Bioresearch, Bob was a key player in acquiring, protecting and developing Knoll’s drug HUMIRA®, and orchestrated the $6.9 Billion acquisition of Knoll AG by Abbott.

Ton Bunt